Shangha Fosun Pharma

Strides Shasun has announced plans to sell Shasun Pharma to its current management, a provider of contract research and manufacturing services in the UK.

The sale consideration is expected to be approximately $36m and will be completed by September 2016.

Shanghai Fosun Pharma has announced a non-binding proposal to acquire Gland Pharma for a purchase consideration ranging between $1bn and $1.5bn.

The company expects that the acquisition will help develop its drug manufacturing and research and development (R&D) capacity.


Image: Shanghai Fosun Pharma expects that the acquisition will help develop its drug manufacturing and research and development (R&D) capacity. Photo: Courtesy of Shanghai Fosun Pharma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.